US Patent

US10821099 — Use of tradipitant in motion sickness

Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2036-03-04 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating or preventing motion sickness using the NK-1 receptor antagonist tradipitant.

USPTO Abstract

Disclosed herein is a method of treating or preventing motion sickness or at least one symptom thereof, comprising treatment with the NK-1 receptor antagonist, tradipitant.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4396`	—

Patent Metadata

Patent number: US10821099
Jurisdiction: US
Classification: Method of Use
Expires: 2036-03-04
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.